Amneal reports fourth quarter and full year 2021 financial results

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) announced its results today for the fourth quarter and full year ended december 31, 2021. “2021 was a transformational year for amneal as we delivered strong financial results, including 18 percent adjusted ebitda growth, and advanced our evolution into a diversified biopharmaceutical company. we continued to deepen our robust r&d pipeline and added compelling assets in key growth areas
AMRX Ratings Summary
AMRX Quant Ranking